The gas sensing capsule can detect and measure gaseous biomarkers in real time to help improve the diagnosis of gut disorders, such as IBS (Irritable Bowel Syndrome) which affect one in five people in their lifetime. When swallowed, the capsule moves through the gastrointestinal system and transmits information, via a handheld device and mobile app to the cloud, for doctors to examine. This will enable targeted treatment, allow earlier relief of symptoms and contribute to reduced healthcare costs.
RMIT has partnered with the Australian digital health startup, Atmo Biosciences, and this significant partnership allows for RMIT’s research and for this world-first technology to be brought into the community where it can create significant impact. RMIT has applied for patents to protect the technology. Atmo Biosciences recently raised $2.5 million in capital to conduct a series of clinical trials to take the gas sensing capsule closer to commercialisation.